Although subsequent studies reported that CNS-specific Cnr1 deficiency alone prevented HFD-induced hepatic steatosis, insulin resistance, and dyslipidemia (42, 43), recent data indicate that peripherally restricted Cnr1 antagonists can indeed prevent this metabolic syndrome (47). Here, CNR1 is linked to Hepatic steatosis.